On July, 17 AngioDynamics, Inc. (ANGO) Analysts See $0.21 EPS

June 27, 2018 - By Carey Conley

AngioDynamics, Inc. (NASDAQ:ANGO) Corporate Logo
Big Money Sentiment increased to 1.46 in 2018 Q1. It has change of 0.20, from 2017Q4’s 1.26. The ratio improved due to AngioDynamics, Inc. positioning: 17 sold and 40 reduced. 25 funds took positions and 58 increased positions. Investors holded 33.90 million in 2017Q4 but now own 34.89 million shares or 2.93% more.
Ajo Ltd Partnership holds 160,908 shs or 0.01% of its capital. Cap One Natl Association invested 0.1% of its capital in AngioDynamics, Inc. (NASDAQ:ANGO). Lapides Asset Mgmt Limited Liability holds 1.62% or 427,100 shs in its capital. Ny State Teachers Retirement System holds 17,610 shs or 0% of its capital. Invesco Limited holds 0% or 230,516 shs in its capital. Parametric Portfolio Assoc Limited Liability Company, Washington-based fund reported 97,147 shs. Foundry Prtn Ltd Liability Co owns 388,070 shs for 0.28% of their capital. Brinker Capital Inc stated it has 12,898 shs or 0.01% of all its holdings. Barclays Pcl holds 0% or 30,769 shs. Alliancebernstein Limited Partnership holds 142,540 shs. 89,798 are held by Pinebridge Limited Partnership. Loomis Sayles & L P reported 575 shs. Citigroup reported 14,857 shs. Texas Permanent School Fund accumulated 0.01% or 24,325 shs. Ls Advsr Ltd Liability Com stated it has 1,331 shs.

AngioDynamics, Inc. (NASDAQ:ANGO)’s earnings report is awaited by WallStreet on July, 17, according to Faxor. Analysts expect change of 10.53 % or $0.02 from previous year’s $0.19 earnings per share compared to current’s $0.21 earnings per share. If ANGO’s EPS is $0.21 the profit will hit $7.73M for 27.38 P/E. Wall Street predicts -16.00 % negative EPS growth as of July, 17. ANGO hit $23 during the last trading session after $0.49 change.AngioDynamics, Inc. has volume of 132,408 shares. Since June 27, 2017 ANGO has risen 30.75% and is uptrending. ANGO outperformed by 18.18% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

A total of 3 analysts rate Angiodynamics (NASDAQ:ANGO) as follows: 1 “Buy”, 2 “Hold” and 0 “Sell”. Тherefore 33% are bullish. (NASDAQ:ANGO) has 5 ratings reports on Jun 27, 2018 according to StockzIntelligence. The company rating was maintained by Canaccord Genuity on Thursday, March 29. The stock rating was upgraded by Raymond James to “Outperform” on Tuesday, April 3. The company rating was downgraded by Craig Hallum on Friday, January 5. On Monday, April 2 the rating was maintained by Canaccord Genuity with “Hold”. The company rating was maintained by Canaccord Genuity on Thursday, January 4.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally.The firm is worth $846.50 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.The P/E ratio is 638.89. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

A couple more AngioDynamics, Inc. (NASDAQ:ANGO) news were posted by: Benzinga.com which released on June 21, 2018 “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street”, also Benzinga.com on June 27, 2018 posted “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading”, the next Benzinga.com is “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018. Globenewswire.com has article titled “Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience …”.

AngioDynamics, Inc. (NASDAQ:ANGO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.